FSTX

NASDAQ

F-star Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2016

$7.12+0.00 (+0.07%)

News25/Ratings4

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Latest news

25 items

655dPR
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e
876dPR
Levicept Appoints Eliot Forster as CEO
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
1131dSEC
SEC Form 15-12G filed by F-star Therapeutics Inc.
15-12G - F-star Therapeutics, Inc. (0001566373) (Filer)
1134d13D/G
SEC Form SC 13G filed by F-star Therapeutics Inc.
SC 13G - F-star Therapeutics, Inc. (0001566373) (Subject)
1137dSEC
SEC Form EFFECT filed by F-star Therapeutics Inc.
EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)
1137dSEC
SEC Form EFFECT filed by F-star Therapeutics Inc.
EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)
1137dSEC
SEC Form EFFECT filed by F-star Therapeutics Inc.
EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)
1137dSEC
SEC Form EFFECT filed by F-star Therapeutics Inc.
EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)
1137dSEC
SEC Form EFFECT filed by F-star Therapeutics Inc.
EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)
1142dINSIDER
SEC Form 4: Kayitalire Louis returned $178,135 worth of shares to the company (25,019 units at $7.12), closing all direct ownership in the company to satisfy tax liability
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Forster Eliot returned $526,588 worth of shares to the company (73,959 units at $7.12), closing all direct ownership in the company (for withholding tax)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4 filed by Klein Pamela M.
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Deptula-Hicks Darlene M returned $181,838 worth of shares to the company (25,539 units at $7.12), closing all direct ownership in the company to cover withholding tax
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Brady Todd C closing all direct ownership in the company (withholding tax)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Brewis Neil returned $66,750 worth of shares to the company (9,375 units at $7.12), closing all direct ownership in the company (for withholding tax)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Race Geoffrey closing all direct ownership in the company to cover taxes
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Benz Edward Jr returned $31,221 worth of shares to the company (4,385 units at $7.12), closing all direct ownership in the company (tax withholding)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Bermingham Nessan returned $45,055 worth of shares to the company (6,328 units at $7.12), closing all direct ownership in the company (for tax liability)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dINSIDER
SEC Form 4: Arkowitz David closing all direct ownership in the company (for withholding tax)
4 - F-star Therapeutics, Inc. (0001566373) (Issuer)
1142dSEC
SEC Form S-8 POS filed by F-star Therapeutics Inc.
S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)
1142dSEC
SEC Form S-8 POS filed by F-star Therapeutics Inc.
S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)
1142dSEC
SEC Form S-8 POS filed by F-star Therapeutics Inc.
S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)
1142dSEC
SEC Form S-8 POS filed by F-star Therapeutics Inc.
S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)
1142dSEC
SEC Form S-8 POS filed by F-star Therapeutics Inc.
S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)
1142dSEC
SEC Form S-8 POS filed by F-star Therapeutics Inc.
S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)